000139970 001__ 139970
000139970 005__ 20240321220723.0
000139970 0247_ $$2doi$$a10.1016/j.parkreldis.2018.02.027
000139970 0247_ $$2pmid$$apmid:29503154
000139970 0247_ $$2ISSN$$a1353-8020
000139970 0247_ $$2ISSN$$a1873-5126
000139970 0247_ $$2altmetric$$aaltmetric:34248018
000139970 037__ $$aDZNE-2020-06292
000139970 041__ $$aEnglish
000139970 082__ $$a610
000139970 1001_ $$0P:(DE-HGF)0$$aGalazky, Imke$$b0$$eCorresponding author
000139970 245__ $$aDeep brain stimulation of the pedunculopontine nucleus for treatment of gait and balance disorder in progressive supranuclear palsy: Effects of frequency modulations and clinical outcome.
000139970 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2018
000139970 264_1 $$2Crossref$$3print$$bElsevier BV$$c2018-05-01
000139970 3367_ $$2DRIVER$$aarticle
000139970 3367_ $$2DataCite$$aOutput Types/Journal article
000139970 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705935691_13659
000139970 3367_ $$2BibTeX$$aARTICLE
000139970 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000139970 3367_ $$00$$2EndNote$$aJournal Article
000139970 520__ $$aThe pedunculopontine nucleus has been suggested as a potential deep brain stimulation target for axial symptoms such as gait and balance impairment in idiopathic Parkinson's disease as well as atypical Parkinsonian disorders.Seven consecutive patients with progressive supranuclear palsy received bilateral pedunculopontine nucleus deep brain stimulation. Inclusion criteria comprised of the clinical diagnosis of progressive supranuclear palsy, a levodopa-resistant gait and balance disorder, age <75 years, and absence of dementia or major psychiatric co-morbidities. Effects of stimulation frequencies at 8, 20, 60 and 130 Hz on motor scores and gait were assessed. Motor scores were followed up for two years postoperatively. Activities of daily living, frequency of falls, health-related quality of life, cognition and mood at 12 months were compared to baseline parameters. Surgical and stimulation related adverse events were assessed.Bilateral pedunculopontine nucleus deep brain stimulation at 8 Hz significantly improved axial motor symptoms and cyclic gait parameters, while high frequency stimulation did not ameliorate gait and balance but improved hypokinesia. This improvement however did not translate into clinically relevant benefits. Frequency of falls was not reduced. Activities of daily living, quality of life and frontal cognitive functions declined, while mood remained unchanged.Bilateral pedunculopontine nucleus deep brain stimulation in progressive supranuclear palsy generates frequency-dependent effects with improvement of cyclic gait parameters at low frequency and amelioration of hypokinesia at high frequency stimulation. However, these effects do not translate into a clinically important improvement.
000139970 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000139970 542__ $$2Crossref$$i2018-05-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000139970 588__ $$aDataset connected to CrossRef, PubMed,
000139970 650_7 $$2Other$$aDeep brain stimulation
000139970 650_7 $$2Other$$aGait
000139970 650_7 $$2Other$$aParkinsonian disorders
000139970 650_7 $$2Other$$aPedunculopontine nucleus
000139970 650_7 $$2Other$$aProgressive supranuclear palsy
000139970 650_7 $$2Other$$aQuality of life
000139970 650_2 $$2MeSH$$aAccidental Falls: prevention & control
000139970 650_2 $$2MeSH$$aActivities of Daily Living
000139970 650_2 $$2MeSH$$aAged
000139970 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000139970 650_2 $$2MeSH$$aCognitive Dysfunction: therapy
000139970 650_2 $$2MeSH$$aDeep Brain Stimulation: methods
000139970 650_2 $$2MeSH$$aFemale
000139970 650_2 $$2MeSH$$aGait Disorders, Neurologic: etiology
000139970 650_2 $$2MeSH$$aGait Disorders, Neurologic: therapy
000139970 650_2 $$2MeSH$$aHumans
000139970 650_2 $$2MeSH$$aHypokinesia: etiology
000139970 650_2 $$2MeSH$$aHypokinesia: therapy
000139970 650_2 $$2MeSH$$aMale
000139970 650_2 $$2MeSH$$aOutcome Assessment, Health Care
000139970 650_2 $$2MeSH$$aPedunculopontine Tegmental Nucleus
000139970 650_2 $$2MeSH$$aPostural Balance
000139970 650_2 $$2MeSH$$aQuality of Life
000139970 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: complications
000139970 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: therapy
000139970 7001_ $$aKaufmann, Jörn$$b1
000139970 7001_ $$aLorenzl, Stefan$$b2
000139970 7001_ $$aEbersbach, Georg$$b3
000139970 7001_ $$aGandor, Florin$$b4
000139970 7001_ $$0P:(DE-HGF)0$$aZaehle, Tino$$b5
000139970 7001_ $$aSpecht, Sylke$$b6
000139970 7001_ $$aStallforth, Sabine$$b7
000139970 7001_ $$0P:(DE-2719)2761749$$aSobieray, Uwe$$b8$$udzne
000139970 7001_ $$aWirkus, Edyta$$b9
000139970 7001_ $$aCasjens, Franziska$$b10
000139970 7001_ $$0P:(DE-2719)2260426$$aHeinze, Hans-Jochen$$b11$$udzne
000139970 7001_ $$aKupsch, Andreas$$b12
000139970 7001_ $$0P:(DE-2719)9000330$$aVoges, Jürgen$$b13$$eLast author$$udzne
000139970 77318 $$2Crossref$$3journal-article$$a10.1016/j.parkreldis.2018.02.027$$b : Elsevier BV, 2018-05-01$$p81-86$$tParkinsonism & Related Disorders$$v50$$x1353-8020$$y2018
000139970 773__ $$0PERI:(DE-600)2027635-7$$a10.1016/j.parkreldis.2018.02.027$$gVol. 50, p. 81 - 86$$p81-86$$q50<81 - 86$$tParkinsonism & related disorders$$v50$$x1353-8020$$y2018
000139970 8564_ $$uhttps://pub.dzne.de/record/139970/files/DZNE-2020-06292_Restricted.pdf
000139970 8564_ $$uhttps://pub.dzne.de/record/139970/files/DZNE-2020-06292_Restricted.pdf?subformat=pdfa$$xpdfa
000139970 909CO $$ooai:pub.dzne.de:139970$$pVDB
000139970 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2761749$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000139970 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2260426$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000139970 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000330$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000139970 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000139970 9141_ $$y2018
000139970 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000139970 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000139970 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000139970 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000139970 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPARKINSONISM RELAT D : 2021$$d2022-11-12
000139970 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000139970 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000139970 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000139970 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000139970 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPARKINSONISM RELAT D : 2022$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000139970 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-24
000139970 9201_ $$0I:(DE-2719)1340007$$kCore Technical Staff$$lCore KAP (Kooperationseinheit Angewandte Präventionsforschung)$$x0
000139970 9201_ $$0I:(DE-2719)7000000$$kU Clinical Researchers - Magdeburg$$lU Clinical Researchers - Magdeburg$$x1
000139970 980__ $$ajournal
000139970 980__ $$aVDB
000139970 980__ $$aI:(DE-2719)1340007
000139970 980__ $$aI:(DE-2719)7000000
000139970 980__ $$aUNRESTRICTED